dyax corp particip upcom investor confer dyax corp nasdaq dyax announc today execut manag particip follow upcom investor confer deutsch bank 40thannual health care confer beingheld may 67 2015 intercontinent hotel boston ma compani present wednesday may 6 450 pm et bank america merril lynch 2015 health care confer held may 1214 2015 encor wynn las vega nv compani present wednesday may 13 1120 pt execut manag provid updat dx2930 kalbitorecallantideand licens fund research portfolio lfrp present webcast live may access visit investor relat section compani websit webcast also avail dyax websit limit period time follow confer dyaxdyax biopharmaceut compani focus develop commerci novel biotherapeut unmet medic need compani develop fulli human monoclon antibodi prevent hereditari angioedema hae attack march 2015 compani report posit safeti pharmacokinet biomark proofofconcept efficaci result itsphase1b clinic trial hae patient addit dyaxmarketskalbitorecallantidefor treatment acut attack hae patient 12 year age olderboth dx2930 kalbitor identifi use dyax proprietari phage display technolog dyax broad licens technolog licensingand fund research portfolio lfrp current portfolio includeson fda approv product eli lilli compani cyramza ramucirumab dyax receiv royalti multipl product candid various stage clinic develop compani elig receiv futur mileston andor royalti addit inform dyax pleas visit addit inform kalbitor includ full prescrib inform pleas press releas contain forwardlook statement statement histor fact base dyax current expect belief assumpt estim forecast project industri market dyax oper statement contain releas guarante futur perform involv certain risk uncertainti assumpt difficult predict therefor actual outcom result may differ materi express forwardlook statement risk uncertainti assumpt involv futur project mani factor could caus actual result differ forwardlook statement includ risk uncertainti relat clinic develop regulatori approv dx2930 dyax depend expertis effort prioriti contractu oblig third parti develop dx2930 market sale distribut kalbitor competit new exist treatment hae uncertainti patent intellectu properti protect relat dx2930 kalbitor lfrp dyax depend license collabor develop clinic trial manufactur sale distribut product candid lfrp uncertainti whether one product candid lfrp achiev develop regulatori mileston commerci generat royalti uncertainti regard lilli abil success market cyramza treatment advanc gastric cancer risk factor describ refer item 1a risk factor dyax recent annual report form 10k period report file secur exchang commiss dyax caution investor place undu relianc forwardlook statement contain releas statement speak date releas dyax undertak oblig updat revis statement except may requir law dyax dyax logo kalbitor regist trademark dyax corp cyramzai trademark own licens eli lilli compani subsidiari affiliatesdyax corpjennif robinson investorrelationsand corpor communicationsjrobinsondyaxcom 